Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

Meanwhile, Lilly gets in on the next-gen KRAS action.

Gilead came out swinging in second-line lung cancer, but it might have just whiffed.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

But will the FDA accept the surrogate endpoint used in ASC4First?

This weekend’s oncology conference will feature at least 30 different ADC projects.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.